Home » Fake Drug Racket Exposed in Himachal’s Baddi, 2 Arrested

Fake Drug Racket Exposed in Himachal’s Baddi, 2 Arrested

Investigators probe source of raw materials, packaging and labels; third accused still absconding

Baddi (Solan): In a disturbing revelation that raises serious questions over drug safety and regulatory oversight in Himachal Pradesh’s pharmaceutical hub, investigators have uncovered an alleged racket in which straw powder was being used to manufacture counterfeit medicines and pass them off as genuine branded drugs.

The operation, detected in a room near Khera bypass in Rajpura, Nalagarh, has exposed how an alleged illegal manufacturing unit was functioning outside the conventional pharmaceutical production system. The Drug Control Department has now intensified its investigation to trace the supply chain of raw materials, packaging and labels used in the operation.

Two persons including Monu Kumar, a resident of Jharkhand, and Mohammad Haseen, from Uttar Pradesh  have been arrested in the case and remanded to police custody until November 23. A third accused is still absconding, with police conducting raids to trace his whereabouts.

Branded medicine packaging under scanner

During the investigation, officials recovered three categories of suspected counterfeit medicines, including antibiotics, neurological drugs and medicines used for acidity-related conditions. The packets carried the names of Alkem, Medwin and Keltex Healthcare, with references to companies based in Sikkim, Ghaziabad and Bada village in Sirmaur, respectively.

Investigators suspect that straw powder was being filled into medicine packaging bearing the names of established pharmaceutical companies, allegedly to make the products appear genuine and facilitate their sale in the market.

The department is contacting the companies concerned to establish whether the packaging and labels were genuine or unauthorised. Investigators are also examining whether the accused had access to a wider distribution network extending beyond Himachal Pradesh.

The bigger question: Who supplied the ingredients?

The probe has now shifted towards identifying the source of the straw powder, labels and packaging material. Investigators are questioning the arrested accused to establish where the material was procured, who financed the operation and whether other people were involved in manufacturing and distribution.

The case also highlights a growing enforcement challenge in the Baddi-Barotiwala-Nalagarh industrial belt, where illegal activities operating from rented rooms and residential premises can escape the scrutiny normally associated with licensed pharmaceutical manufacturing facilities.

This is not the first time the region has figured in counterfeit drug investigations. Earlier, a suspected fake medicine racket was detected in Baddi’s Sheetalpur area, while in 2022, eight people were arrested in connection with counterfeit medicines allegedly being supplied to Agra from a closed factory near Hanuman Temple in Baddi.

According to the reported enforcement figures, 12 cases of counterfeit drug manufacturing have been detected in Himachal Pradesh so far, leading to 21 arrests.

Quality concerns add to the regulatory challenge

The latest exposure comes against the backdrop of wider concerns over pharmaceutical quality in the state. The September report of the Central Drugs Standard Control Organisation reportedly found 330 drug samples across the country failing prescribed quality standards, including batches attributed to 92 pharmaceutical units in Himachal Pradesh.

The state drug regulatory administration has directed that the affected batches should not be used and that action be initiated against the concerned units.

While the Rajpura case involves allegations of deliberate counterfeit manufacturing, the quality-failure findings represent a separate regulatory concern. Together, they underline the need for stronger surveillance, traceability of pharmaceutical ingredients and effective inspections.

For consumers, the danger goes beyond counterfeit packaging. Medicines containing unidentified or inappropriate substances can fail to treat illnesses and may expose patients to serious health risks. The investigation will now determine how far the alleged racket extended and whether counterfeit products had already reached unsuspecting consumers.

For a state that has built its reputation as one of India’s major pharmaceutical manufacturing destinations, the case presents an uncomfortable question: how effectively are the authorities monitoring medicines before they reach patients?

Leave a Reply

Your email address will not be published. Required fields are marked *